

ODJFS P&T Committee Meeting Minutes

January 27, 2010

77 S. High St., Room 1960

Committee members present: Susan Baker, APN; Suzanne Eastman, RPh; Cheryl Huffman, MD; Robert L. Hunter, DO (chair); Karen Jacobs, DO; Margaret Scott, RPh; Michael Wascovich, RPh; Mary Jo Welker, MD

ACS staff present: Stephanie Levine, PharmD, Clinical Manager

Approximately 50 stakeholders were present, most representing pharmaceutical manufacturers, provider associations, and advocacy associations.

The meeting was called to order at 10:04 AM.

1. Conflict of interest statement. All Committee members present signed the conflict of interest statement.
2. Discussion about policy regarding interested party presentations.
Ms. Scott reviewed the minutes from the January discussion on this topic, and went through the draft that was distributed with the agenda. The Committee recommended only one change, that the requestor should be notified the Friday prior to the meeting whether they will be able to submit written information or make a presentation. Ms. Scott will consult with the ODJFS Office of Legal and Acquisition Services to be sure that the policy meets the requirements of Ohio Revised Code section 5111.084(D).
3. Interested party presentations. No requests for presentations were received.
4. Drugs under consideration
 - a. Attention Deficit Hyperactivity Disorder Agents: Intuniv (guanfacine extended release tablets), Shire
A speaker provided by Shire presented information. Committee members asked about side effects, adult dosing, cost, and whether the drug is considered a first-line drug. Dr. Hunter suggested changing the criteria for approval of non-preferred drugs to a trial on one drug. Dr. Huffman said a trial on two drugs is not unreasonable. Dr. Jacobs and Dr. Welker asked if psychiatrists are or should be exempt from prior authorization criteria.
The P&T Committee unanimously made three recommendations: 1) Intuniv should be limited to patients under the age of 18; 2) psychiatrists should be exempt from prior authorization requirements for attention deficit hyperactivity disorder drugs; 3) Intuniv should be non-preferred on the Preferred Drug List (PDL)
 - b. Ophthalmic antibiotics: Besivance (besifloxacin ophthalmic suspension), Bausch & Lomb
A speaker provided by Bausch & Lomb presented information. Committee members asked about length of therapy and whether initial treatment with a quinolone will contribute to antibiotic resistance. Dr. Jacobs asked if it is possible to exempt optometrists and ophthalmologists from prior authorization

requirements. Ms. Scott said that it is possible, but that continuing to exempt specialists may not be the best policy.

The P&T Committee unanimously recommended that Besivance should be non-preferred on the PDL.

- c. Analgesics: Embeda (morphine sulfate and naltrexone HCl extended release tablets) CII, King

A speaker provided by King provided information. Committee members asked about cost. Ms. Scott reviewed the prior authorization criteria for opioid drugs, failure of two unrelated long-acting products, meaning that for Embeda to be approved the patient would need to try two other non-morphine drugs.

The P&T Committee unanimously recommended that Embeda should be non-preferred on the PDL.

The next meeting is scheduled for Wednesday, April 21, 2010, at 10 AM in the Rhodes State Office Tower, 30 E. Broad St., room 2925.

The meeting was adjourned at 11:01 AM by Dr. Hunter.

Following the meeting, ODJFS followed the Committee's recommendations to make Intuniv, Besivance, and Embeda non-preferred. Recommendations about exemption of psychiatrists from prior authorization of attention deficit hyperactivity disorder drugs and the policy on interested party presentations are under review by ODJFS.

UPDATE 4/21/10: ODJFS will not exempt psychiatrists from prior authorization of attention deficit hyperactivity disorder drugs. The interested party presentation guidelines were adopted at the 4/21/10 committee meeting and the final policy appears in the minutes from that meeting.